Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial
Main Article Content
Keywords
psoriasis, moderate to severe, POETYK, deucravacitinib, TYK2 inhibitor
Abstract
N/A
References
1. Armstrong AW, et al. J Am Acad Dermatol. 2022;S0190-9622 [online ahead of print].
2. Armstrong AW, et al. [poster] Presented at the American Academy of Dermatology Annual Meeting, March 25–29, 2022,
Boston, MA.
3. Armstrong AW, et al. J Dermatolog Treat. 2017;28:200-205.
4. Bushmakin AG, et al. Qual Life Res. 2011;20:491-498.
5. Warren RB, et al. J Eur Acad Dermatol Venereol. 2021;35:450-457.
6. Blauvelt A, et al. J Manag Care Spec Pharm. 2021;27:84-94.
2. Armstrong AW, et al. [poster] Presented at the American Academy of Dermatology Annual Meeting, March 25–29, 2022,
Boston, MA.
3. Armstrong AW, et al. J Dermatolog Treat. 2017;28:200-205.
4. Bushmakin AG, et al. Qual Life Res. 2011;20:491-498.
5. Warren RB, et al. J Eur Acad Dermatol Venereol. 2021;35:450-457.
6. Blauvelt A, et al. J Manag Care Spec Pharm. 2021;27:84-94.